Mineralys Therapeutics Inc MLYS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
13.52UNCH (UNCH)
Volume
2,199
Close
13.52quote price arrow down-0.75 (-5.26%)
Volume
119,395
52 week range
5.85 - 17.44
Loading...
  • Open14.05
  • Day High14.21
  • Day Low13.12
  • Prev Close14.27
  • 52 Week High17.44
  • 52 Week High Date06/30/23
  • 52 Week Low5.85
  • 52 Week Low Date11/22/23

Key Stats

  • Market Cap671.013M
  • Shares Out49.63M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change57.21

KEY STATS

  • Open14.05
  • Day High14.21
  • Day Low13.12
  • Prev Close14.27
  • 52 Week High17.44
  • 52 Week High Date06/30/23
  • 52 Week Low5.85
  • 52 Week Low Date11/22/23
  • Market Cap671.013M
  • Shares Out49.63M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change57.21

RATIOS/PROFITABILITY

  • EPS (TTM)-2.18
  • P/E (TTM)-6.19
  • Fwd P/E (NTM)-4.76
  • EBITDA (TTM)-105.073M
  • ROE (TTM)-29.11%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mineralys Therapeutics Inc

 

Profile

MORE
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension...
Brian Slingsby M.D., Ph.D.
Executive Chairman of the Board, Founder
Jon Congleton
Chief Executive Officer, Director
Adam Levy
Chief Financial Officer, Company Secretary
Address
150 N. Radnor Chester Road, Suite F200
Radnor, PA
19087
United States

Top Peers

SYMBOLLASTCHG%CHG
SVRA
Savara Inc
4.66-0.42-8.19%
ORIC
Oric Pharmaceuticals Inc
8.99-0.51-5.37%
PRME
Prime Medicine Inc
5.61-0.11-1.92%
HLVX
Hillevax Inc
13.84-0.15-1.07%
GHRS
GH Research PLC
12.81+0.82+6.84%